This product is currently not available for purchase.


Molecular Determinants of Glioma Risk and Patient Prognosis. Edition No. 1

  • ID: 1920436
  • February 2012
  • 188 Pages
  • VDM Publishing House
1 of 3

Gliomas encompass a wide variety of particularly devastating tumors, for which efficient therapies are not available. Their etiology remains mostly undetermined: so far, only exposure to high-dose therapeutic radiation has been firmly established as a risk factor, but other plausible causes include genetic syndromes, familial aggregation, and genetic polymorphisms. The clinical performance status and patient age at diagnosis are definite features associated with outcome, but recent evidences suggest that tumor’s molecular traits are also major determinants of prognosis. This book aims to review and discuss how molecular determinants may affect glioma risk and patient outcome, with a very special emphasis in glioblastoma multiforme, the most common and malignant glioma subtype. To do so, Part I presents a general introduction that summarizes the classification, epidemiology, and treatment of gliomas, while devoting particular attention to potential etiological factors and molecular alterations of these tumors. Part II presents original research studies emphasizing the relevance of particular biomarkers of glioma, particularly at the levels of glioma risk and patient prognosis.

Note: Product cover images may vary from those shown
2 of 3

The author Mrs. Serah Wambui Muriu , has a Masters of Education (Early Childhood Studies) from Kenyyatta University and over thirty years experience at various deployment in primary education. Currently, studying for PhD (E C S) and teaching at Kenyatta University Kenya.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


If you have a more general question about our products please try our


Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.